Alzheimer’s Drugs Currently Banned May Benefit Brain
Alzheimer’s drugs currently being denied to some NHS patients may have a dramatic impact on the pathology of the brain, research in the UK indicates.
The study found that proteins linked to plaques in the brain associated with Alzheimer’s disease and other forms of dementia were 70 per cent less in people given treatment with these drugs than those who were not.
Published in the journal Neurology, it is the first study to analyse the effects of cholinesterase inhibitors on the human brain.
The cholinesterase drugs donepezil, rivastagmine and galantamine work by protecting the communication process between brain cells from plaques and tangles caused by certain proteins.
Campaigners are currently working to make sure the drugs are available to people with all stages of the disease. In November last year the National Institute of Health and Clinical Excellence (Nice) recommended that they only be available to people in the moderate stages of the disease.
You may also like to read
- Alzheimer May Be Prevented By MegaNatural AZ
- NICE Denies UK Lung Cancer Patients a New Lease of Life (Tarceva)
- Clinical Trial For Alzheimer's Drug 'Aricept' Kills Eleven
- Drug Development for Dementia Under Study After Researchers Find the Cause of Memory Loss
- Steroid Treatments for Brain Injury May Boost Death Risk
